Spots Global Cancer Trial Database for Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Official Title: Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Study ID: NCT06419634
Interventions
Study Description
Brief Summary: The purpose of this study is to assess the safety, tolerability, drug levels, drug efficacy and determine the recommended dose of BMS-986497 in participants with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 0011, New Haven, Connecticut, United States
Local Institution - 0010, Chicago, Illinois, United States
Local Institution - 0007, Boston, Massachusetts, United States
Local Institution - 0014, Boston, Massachusetts, United States
Local Institution - 0013, Saint Louis, Missouri, United States
Local Institution - 0008, Hackensack, New Jersey, United States
Columbia University Irving Medical Center, New York, New York, United States
Local Institution - 0006, Houston, Texas, United States
Local Institution - 0009, Fairfax, Virginia, United States
Local Institution - 0002, Toronto, Ontario, Canada
Local Institution - 0003, Montreal, Quebec, Canada
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
